Internal Medicine, Hematology & Oncology · Oklahoma City, OK
NPI
1265619530
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
800 NE 10th St
Oklahoma City, OK, 73104
Phone (405) 271-4022
Groups this clinician bills Medicare through
Medicare paid, 2024
$48K
750 services
Medicare patients, 2024
317
Average age 72
Drug cost, 2024
$4.6M
1,814 prescriptions
Company payments, 2025
$1,052
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wajeeha Razaq was code 99214 (office e&m - established), 415 times for 248 patients. In total Wajeeha Razaq billed 750 services in 12 codes, and Medicare paid $48K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-08-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 415 | 248 | $63.37 | $26K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 144 | 136 | $11.71 | $1,686 |
| 99215 Office E&M - Established | Office | 101 | 54 | $102.34 | $10K |
| 99223 Hospital E&M - Initial | Facility | 33 | 33 | $129.11 | $4,261 |
| 99205 Office E&M - New | Office | 31 | 31 | $117.26 | $3,635 |
By year: 2022 $75K for 796 services; 2023 $39K for 498 services; 2024 $48K for 750 services.
Medicare prescription drug claims, 2024
In 2024, the drug Wajeeha Razaq prescribed most often to Medicare patients was Anastrozole, with 581 prescriptions and refills. In total Wajeeha Razaq wrote 1,814 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 581 | 1,438 | 159 | $25K |
| Exemestane Generic | 155 | 314 | 45 | $20K |
| Letrozole Generic | 133 | 345 | 43 | $3,955 |
| Ibrance Palbociclib | 118 | 118 | 14 | $1.8M |
| Kisqali Ribociclib Succinate | 95 | 95 | 12 | $1.2M |
| Ondansetron Hcl Generic | 77 | 78 | 36 | $3,269 |
| Gabapentin Generic | 63 | 85 | 17 | $593 |
| Verzenio Abemaciclib | 59 | 59 | 11 | $838K |
| Venlafaxine Hcl Er Venlafaxine Hcl | 57 | 97 | 13 | $1,354 |
| Potassium Chloride Generic | 37 | 43 | 24 | $181 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 37 | 41 | 23 | $525 |
| Eliquis Apixaban | 36 | 38 | Under 11 | $20K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 35 | 35 | 11 | $1,004 |
| Everolimus Generic | 34 | 34 | Under 11 | $125K |
| Alendronate Sodium Generic | 24 | 48 | Under 11 | $682 |
Brand drugs: 464 claims; generic drugs: 1,350 claims; opioid claims: 69.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wajeeha Razaq $1,052 ($1,052 in general payments such as food, travel and fees) from 15 companies. The largest payer was Genentech, Inc. with $233.
| Company | Payments | Amount |
|---|---|---|
| Genentech, Inc. ROG.SW | 2 | $233 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $157 |
| Caris MPI, Inc. | 2 | $105 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $99.64 |
| Stemline Therapeutics Inc. | 4 | $79.74 |
| Pfizer Inc. PFE | 7 | $76.04 |
| Daiichi Sankyo Inc. 4568.T | 3 | $67.11 |
| Eisai Inc. 4523.T | 2 | $50.42 |
| Merck Sharp & Dohme LLC MRK | 2 | $43.48 |
| Gilead Sciences, Inc. GILD | 2 | $42.36 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.